Themis Medicare shareholders approve related party transactions and warrant issuance via postal ballot.
Themis Medicare Limited shareholders approved four resolutions via postal ballot. These include related party transactions with Themis Distributors, Vividhmargi Investments, Gujarat Themis Biosyn, and Dr. Sachin D. Patel (up to ₹130 crore). A special resolution also passed for issuing convertible warrants to Vividhmargi Investments on a preferential basis.
The approval of related party transactions and preferential issuance of warrants can have a significant impact on the company's financial structure and relationships with associated entities.
The company successfully passed all proposed resolutions through a postal ballot, indicating shareholder approval for key corporate actions, including related party transactions and the issuance of warrants.
Themis Medicare Limited has announced the results of its postal ballot, with shareholders approving four resolutions. The resolutions passed include the approval of material related party transactions with Themis Distributors Private Limited or Vividhmargi Investments Private Limited (VMIPL) post-merger.
Shareholders also approved material related party transactions with Gujarat Themis Biosyn Limited (GTBL). Additionally, an ordinary resolution was passed for the approval of material related party transactions with Dr. Sachin D. Patel, involving an inter-se transfer of equity shares of Gujarat Themis Biosyn Limited (GTBL) held by Themis Medicare Limited (TML), up to ₹130 crores.
Furthermore, a special resolution was passed for the issuance of convertible warrants to Vividhmargi Investments Private Limited, a promoter group company, on a preferential basis. The voting results and the Scrutinizer’s Report, dated 27th March, 2026, confirm that all proposed resolutions were passed by the shareholders with the requisite majority through remote e-voting. The details of the voting results will be made available on the company's website.
What to do with a filing like this
Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under shareholder meetings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.